chartexchange

Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting

GlobeNewswire Inc. | Nov 4, 2026 9:01 AM EST

Gamgertamig data from ongoing Phase 1b studies suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an “immune reset ”

Read original article